久久久久久国产精品免费免,日本欧美国产精品第一页久久,日韩精品久久久久影院,国产在线麻豆精品,97人人模人人爽视频一区二区

人肺癌細(xì)胞帶紅色熒光 A549+RFP

種屬	人
別稱	A549+RFP
組織來(lái)源	肺
疾病	肺腺癌
傳代比例/細(xì)胞消化	1：2-1:3傳代，消化3-5分鐘
培養(yǎng)基配置	Ham's F-12K培養(yǎng)基；10%胎牛血清；1%雙抗
簡(jiǎn)介	該細(xì)胞系由D.J.Griad通過(guò)肺癌組織移植培養(yǎng)建系，患者為58歲白人男性。A549能通過(guò)胞苷二磷酸途徑合成含有高含量不飽和脂肪酸的。
形態(tài)	上皮細(xì)胞樣
生長(zhǎng)特征	貼壁生長(zhǎng)
倍增時(shí)間	~22h
STR	Amelogenin：X ，Y；CSF1PO：10 ，12；D13S317：11；D16S539：11 ，12；D18S51：14 ，17； D19S433：13；D21S11：29；D2S1338：24；D3S1358：16；D5S818：11；D7S820：8 ，11；D8S1179： 13 ，14；FGA：23；TH01：8 ，9.3；TPOX：8 ，11；vWA：14；
培養(yǎng)條件	氣相：空氣，95% ；二氧化碳，5%。溫度：37攝氏度，培養(yǎng)箱濕度為70%-80%。
凍存條件	凍存液：90%FBS ，DMSO 10%, 或使用非程序凍存液：貨號(hào)JY-H040
備注	該細(xì)胞是通過(guò)慢病毒轉(zhuǎn)染熒光素酶的穩(wěn)轉(zhuǎn)株，收到細(xì)胞傳代8代左右后，若要求需要維持熒光強(qiáng)度，建議可以加入嘌呤霉素進(jìn)行再次篩選。
產(chǎn)品使用	于科學(xué)研究，不可作為動(dòng)物或人類疾病的治療產(chǎn)品使用。

pathways[J]. Mol Cell Biochem, 2017, 428(1-2):41-56.
[ ARRIETA-CRUZ I, SU Ya, KNIGHT C M, et al.
Evidence for a role of proline and hypothalamic
astrocytes in the regulation of glucose metabolism
in rats[J]. Diabetes, 2013, 62(4):1152-8.

infiltration was reduced , cells were more neatly ar- ranged and fibrous hyperplasia improved; compared with the NC group , the HC group showed significantly higher Ishak score , Ishak stage , liver index , Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for patients with non-homologous recombination deficient (HRD) disease. Folate receptor alpha (FOLR1/FRα)-targeting agents have shown promise both alone and in combination with available therapies, but the relationship of FRα to other treatment-driving biomarkers is unknown. The Cancer Genome Atlas (TCGA) was queried to assess protein and mRNA expression and mutational burden in patients with differential FRα protein-expressing ovarian tumors, and the results referenced against the standard 324 mutations currently tested through FoundationOne Companion Diagnostics to identify targets of interest. Of 585 samples within TCGA, 121 patients with serous ovarian tumors for whom FRα protein expression was quantified were identified. FRα protein expression significantly correlated with FOLR1 mRNA expression (p=7.19×10 ^- ¹⁴ ). Progression free survival (PFS) for the FRα-high group (Q1) was 20.7 months, compared to 16.6 months for the FRα-low group (Q4, Logrank, p=0.886). Overall survival (OS) was 54.1 months versus 36.3 months, respectively; however, this result was not significant (Q1 vs. Q4, Logrank, p=0.200). Mutations more commonly encountered in patients with high FRα-expressing tumors included PIK3CA and FGF family proteins. Combinations of FRα-targeting agents with PI3K, mTOR, FGF(R) and VEGF inhibitors warrant investigation to evaluate their therapeutic potential.